[1] JEMAL A,SIEGEL R,WARD E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-249.
[2] YOULDEN D R,CRAMB S M,BAADE P D.The international epidemiology of lung cancer:geographical distribution and secular trends[J].J Thorac Oncol,2008,3(8):819-831.
[3] LJUNGGREN H G,MALMBERG K J.Prospects for the use of NK cells in immunotherapy of human cancer[J].Nat Rev Immunol,2007,7(5):329-339.
[4] 蔡枫,何贞月,姜婷婷,等.肿瘤微环境中的树突状细胞及其在肿瘤治疗中的作用[J].东南大学学报:医学版,2012,31(2):225-229.
[5] 李红英,王蓉,汪蕾.沉默microRNA-20a对乳腺癌MCF7细胞表达NK细胞活化性受体配体MICA的研究[J].现代医学,2014,42(1):22-25.
[6] LINN Y C,LAU L C,HUI K M.Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts[J].Br J Haematol,2002,116(1):78-86.
[7] HONTSCHA C,BORCK Y,ZHOU H,et al.Clinical trials on CIK cells:first report of the international registry on CIK cells(IRCC)[J].J Cancer Res Clin Oncol,2010,137(2):305-310.
[8] MORETTA A,BOTTINO C,VITALE M,et al.Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis[J].Annu Rev Immunol,2001,19:197-223.
[9] EAGLE R A,TROWSDALE J.Promiscuity and the single receptor:NKG2D[J].Nat Rev Immunol,2007,7(9):737-744.
[10] LINN Y C,LAU S K,LIU B H,et al.Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell[J].Immunology,2009,126(3):423-435.
[11] WANG Q J,HANADA K,YANG J C.Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas[J].J Immunol,2008,181(6):3769-3776.
[12] ZAFIROVA B,WENSVEEN F M,GULIN M,et al.Regulation of immune cell function and differentiation by the NKG2D receptor[J].Cell Mol Life Sci,2011,68(21):3519-3529.
[13] CHAMPSAUR M,LANIER L L.Effect of NKG2D ligand expression on host immune responses[J].Immunol Rev,2010,235(1):267-285.
[14] FUERTES M B,GIRART M V,MOLINERO L L,et al.Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity[J].J Immunol,2008,180(7):4606-4614.
[15] OGASAWARA K,LANIER L L.NKG2D in NK and T cell-mediated immunity[J].J Clin Immunol,2005,25(6):534-540.
[16] 何金媛,贾祝霞,蔡晓辉,等.NKG2D在细胞因子诱导的杀伤性细胞(CIK)抗血液肿瘤细胞的作用[J].中国实验血液学杂志,2013,21(6):1380-1384. |